Since 2018, clinical guidelines have recommended that patients with low‐risk prostate cancer (PCa) consider active surveillance (AS),1, 2, 3 which involves serial prostate specific antigen (PSA) testing, digital rectal examination, and prostate needle biopsy.4 This evidence concerns the gene KLK3 and Familial prostate cancer.